Literature DB >> 29080081

Cost-effectiveness evaluation of pre-counseling telephone interviews before face-to-face genetic counseling in cancer genetics.

Gaëlle Collet1, Nathalie Parodi1, Kevin Cassinari1, Zoe Neviere1,2, Fanny Cohen2, Céline Gasnier2, Afane Brahimi1, François Lecoquierre1, Jean-Christophe Thery1,3, Isabelle Tennevet1,3, Elodie Lacaze4, Pascaline Berthet2, Thierry Frebourg5,6.   

Abstract

One of the main challenges in cancer genetics is responding to the exponential demand for genetic counseling, especially in patients with breast and/or ovarian cancer. To address this demand, we have set up a new procedure, based on pre-genetic counseling telephone interviews (PTI) followed by routing of patients: D1, a PTI is scheduled within 14 days; D7-D14, genetic counselors perform a 20 min PTI in order to establish a pre-genetic counseling file, by collecting personal and family medical history via a structured questionnaire and; D10-17, routing: pre-genetic counseling appointment files are analyzed by a cancer geneticist with 3 possible conclusions: (a) priority face-to-face genetic counseling (FTFGC) appointment with a cancer geneticist, if the genetic test results have an immediate therapeutic impact; (b) non-priority FTFGC with a genetic counselor, or (c) no FTFGC required or substitution by a more appropriate index case. In the context of breast and/or ovarian cancer, 1012 patients received PTIs, 39.1% of which did not lead to FTFGC. The mean delay for non-priority FTFGC was maintained at 18 weeks and priority FTFGC appointments were guaranteed within 8 weeks. The required resources for 1012 patients was estimated at 0.12 FTE secretaries, 0.62 FTE genetic counselors and 0.08 FTE cancer geneticists and the procedure was shown to be cost-effective. This new procedure allows the suppression of up to 1/3 of appointments, guarantees priority for appointments with therapeutic impact and optimizes the interaction and breakdown of tasks between genetic counselors and cancer geneticists.

Entities:  

Keywords:  Breast cancer; Genetic counseling; Genetic counselors; Ovarian cancer; Routing; Telephone interviews

Mesh:

Year:  2018        PMID: 29080081     DOI: 10.1007/s10689-017-0049-z

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  17 in total

Review 1.  Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis.

Authors:  Antonis Valachis; Andreas D Nearchou; Pehr Lind
Journal:  Breast Cancer Res Treat       Date:  2014-02-25       Impact factor: 4.872

2.  Randomized Noninferiority Trial of Telephone Delivery of BRCA1/2 Genetic Counseling Compared With In-Person Counseling: 1-Year Follow-Up.

Authors:  Anita Y Kinney; Laurie E Steffen; Barbara H Brumbach; Wendy Kohlmann; Ruofei Du; Ji-Hyun Lee; Amanda Gammon; Karin Butler; Saundra S Buys; Antoinette M Stroup; Rebecca A Campo; Kristina G Flores; Jeanne S Mandelblatt; Marc D Schwartz
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

3.  Risk Perception and Psychological Distress in Genetic Counselling for Hereditary Breast and/or Ovarian Cancer.

Authors:  G Cicero; R De Luca; P Dorangricchia; G Lo Coco; C Guarnaccia; D Fanale; V Calò; A Russo
Journal:  J Genet Couns       Date:  2017-03-10       Impact factor: 2.537

Review 4.  PARP inhibitors in ovarian cancer: evidence, experience and clinical potential.

Authors:  Tarra Evans; Ursula Matulonis
Journal:  Ther Adv Med Oncol       Date:  2017-02-03       Impact factor: 8.168

5.  Impact of Panel Gene Testing for Hereditary Breast and Ovarian Cancer on Patients.

Authors:  Heidi S Lumish; Hallie Steinfeld; Carrie Koval; Donna Russo; Elana Levinson; Julia Wynn; James Duong; Wendy K Chung
Journal:  J Genet Couns       Date:  2017-03-29       Impact factor: 2.537

6.  Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation.

Authors:  Dirk Müller; Marion Danner; Kerstin Rhiem; Björn Stollenwerk; Christoph Engel; Linda Rasche; Lisa Borsi; Rita Schmutzler; Stephanie Stock
Journal:  Eur J Health Econ       Date:  2017-04-05

7.  An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers.

Authors:  Dana Madorsky-Feldman; Miri Sklair-Levy; Tamar Perri; Yael Laitman; Shani Paluch-Shimon; Rita Schmutzler; Kerstin Rhiem; Jenny Lester; Beth Y Karlan; Christian F Singer; Tom Van Maerken; Kathleen Claes; Joan Brunet; Angel Izquierdo; Alex Teulé; Jong Won Lee; Sung-Won Kim; Banu Arun; Anna Jakubowska; Jan Lubinski; Katherine Tucker; Nicola K Poplawski; Liliana Varesco; Luigina Ada Bonelli; Saundra S Buys; Gillian Mitchell; Marc Tischkowitz; Anne-Marie Gerdes; Caroline Seynaeve; Mark Robson; Ava Kwong; Nadine Tung; Nalven Tessa; Susan M Domchek; Andrew K Godwin; Johanna Rantala; Brita Arver; Eitan Friedman
Journal:  Breast Cancer Res Treat       Date:  2016-04-27       Impact factor: 4.872

8.  The BOADICEA model of genetic susceptibility to breast and ovarian cancer.

Authors:  A C Antoniou; P P D Pharoah; P Smith; D F Easton
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

9.  High Satisfaction and Low Distress in Breast Cancer Patients One Year after BRCA-Mutation Testing without Prior Face-to-Face Genetic Counseling.

Authors:  Aisha S Sie; Liesbeth Spruijt; Wendy A G van Zelst-Stams; Arjen R Mensenkamp; Marjolijn J L Ligtenberg; Han G Brunner; Judith B Prins; Nicoline Hoogerbrugge
Journal:  J Genet Couns       Date:  2015-11-04       Impact factor: 2.537

10.  Identifying Needs: a Qualitative Study of women's Experiences Regarding Rapid Genetic Testing for Hereditary Breast and Ovarian Cancer in the DNA BONus Study.

Authors:  Mirjam Tonheim Augestad; Hildegunn Høberg-Vetti; Cathrine Bjorvatn; Ragnhild Johanne Tveit Sekse
Journal:  J Genet Couns       Date:  2016-07-28       Impact factor: 2.537

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.